China Plasma Protein Therapeutics Market Outlook: Projected to Reach More Than US$7.7 Billion by 2031 with a 5.7% CAGR | TMR Insights

The China plasma protein therapeutics market, valued at US$4.3 billion in 2021, is anticipated to experience steady growth over the next decade. It is projected to grow at a compound annual growth rate (CAGR) of 5.7% from 2022 to 2031, surpassing US$7.7 billion by the end of 2031. This robust expansion reflects China's increasing demand for plasma-derived treatments, driven by a rising prevalence of chronic diseases, an aging population, and advancements in healthcare infrastructure. As the nation strengthens its biopharmaceutical sector, the market is poised to nearly double in value, reinforcing its critical role in addressing complex medical needs through 2031.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85322

Understanding the China Plasma Protein Therapeutics Market

Plasma protein therapeutics are biologic drugs derived from human plasma, including immunoglobulins, albumin, clotting factors, and protease inhibitors, used to treat conditions like immune deficiencies, hemophilia, and hypoalbuminemia. The market in China encompasses production, distribution, and clinical use of these therapies, often administered in hospitals or specialty clinics. The 2021 valuation of US$4.3 billion underscores its established importance, with the projected rise to over US$7.7 billion by 2031 highlighting its response to growing therapeutic demands.

The 5.7% CAGR signals a dynamic yet stable growth phase, balancing supply constraints with rising clinical adoption. Plasma therapeutics' role in life-saving treatments drives sustained market momentum in China.

Key Drivers of Market Growth

Several factors are propelling the China plasma protein therapeutics market toward its US$7.7 billion milestone by 2031. First, the increasing prevalence of chronic and rare diseases is a primary driver. Conditions like primary immunodeficiency diseases (PIDD), affecting over 6 million globally, and hemophilia, with a growing diagnosed population in China, boost demand for immunoglobulins and clotting factors. An aging population-expected to reach 28% of China's total by 2040-further aligns with the market's 5.7% CAGR, as elderly patients require albumin for critical care.

Second, government support and healthcare reforms are accelerating growth. China's Healthy China 2030 initiative prioritizes biopharmaceutical development, including plasma fractionation capacity. Policies easing restrictions on plasma collection and foreign investment-such as partnerships with global firms like CSL Behring-enhance supply, driving the market toward US$7.7 billion as domestic production scales.

Third, rising healthcare expenditure and awareness are boosting the market. With per capita health spending increasing and insurance coverage expanding under the National Healthcare Security Administration, patients gain better access to expensive plasma therapies. Growing physician and patient education on rare disease management supports adoption, reinforcing the market's trajectory through 2031.

Leading Players:

Biognosys AG
Biotest AG
Taibang Biological Group
CSL Behring
Grifols, S.A.
Kedrion S.p.A.
Octapharma AG
Takeda Pharmaceutical Company Limited
Shanghai RAAS

Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85322

Market Segmentation and Regional Insights

The market segments by product type, application, and geography. Immunoglobulins lead due to their use in PIDD and autoimmune disorders, followed by albumin for shock and burns, and clotting factors for bleeding disorders. Applications include immunology, hematology, and critical care, with immunology showing rapid growth. Distribution occurs via hospital pharmacies, specialty clinics, and retail channels, with hospitals dominating due to inpatient needs.

Within China, eastern coastal regions like Shanghai and Guangdong held a significant share of the US$4.3 billion valuation in 2021, driven by advanced healthcare hubs and higher plasma collection rates. Western provinces, however, are expected to see faster growth through 2031, fueled by healthcare infrastructure expansion and rising diagnosis rates in rural areas, supported by central government investments.

Challenges and Opportunities

The market faces challenges. Plasma supply shortages-China collects only 9 million liters annually versus a potential demand of 15 million-limit production, while stringent regulations on donor eligibility constrain growth. High costs of therapies (e.g., IVIG at thousands per course) and reimbursement gaps in less-developed regions hinder access. The 5.7% CAGR reflects a market navigating these supply-demand imbalances.

These challenges, however, present opportunities. Companies expanding plasma collection centers or developing recombinant alternatives could alleviate shortages, supporting the push to US$7.7 billion. Innovations in fractionation efficiency and biosimilars offer growth potential, while public-private partnerships to boost donor awareness could exceed projections. Expanding telemedicine for rare disease monitoring could further enhance reach.

The Road to 2031

By 2031, the China plasma protein therapeutics market is projected to surpass US$7.7 billion, reflecting ten years of steady growth at a 5.7% CAGR from US$4.3 billion in 2021. This milestone is driven by disease prevalence, policy support, and healthcare advancements. As the forecast concludes, the market's trajectory suggests continued expansion, with potential for synthetic plasma proteins to shape future growth.

In conclusion, the China plasma protein therapeutics market demonstrates solid growth from 2022 to 2031. Rising from US$4.3 billion to over US$7.7 billion, it addresses critical health needs with impactful solutions. Stakeholders-from biopharma firms to policymakers-play a vital role in this success, ensuring effective, accessible treatments meet China's evolving demands through 2031 and beyond.

Explore Latest Research Reports by Transparency Market Research:

Veterinary Ventilators Market: https://www.pharmiweb.com/press-release/2025-03-18/veterinary-ventilators-market-to-surpass-us-13-bn-by-2035-amid-rising-demand-for-advanced-animal-healthcare-solutions-tmr-research

Wearable Pulse Oximeters Market: https://www.pharmiweb.com/press-release/2025-03-18/wearable-pulse-oximeters-market-to-surpass-us-5945-mn-by-2031-amid-rising-demand-for-smart-health-monitoring-solutions-tmr-research

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.